Arabio locally produces human vaccines catering to needs of Arab world and also for export
Mekkah, KSA; Dubai, UAE, 29th January, 2012: Arabio, the only Arab company specialized in manufacturing biological products and vaccines, has appointed Alphamed Group, a leading drug distributor in the UAE owned by Al Khayyat Investments, to represent it in the UAE market.
According to the distribution agreement signed by Dr. Majed Bahatheq, General Manager, Arabio, and Dr. Mohamed Barham, General Manager, Alphamed Group, Alphamed will be responsible for selling Arabio's wide range of human vaccines and drugs in the UAE market.
Dr. Majed Bahatheq, General Manager, Arabio said: "It is a matter of pride to be the only and leading company in the Arab world that specializes in the production of vaccines and other biologicals. We are pleased to appoint Alphamed to represent us in the UAE, and this will go a long way in making more Arab-made vaccines available in the UAE market."
Dr. Barham added: "We are pleased to sign this agreement with Arabio which is one of the pillars in the area of preventive medicine in the Arab world. We share with the company the passion for bringing something new to the Arab world that will add value not only short term but also will lead to a safer life."
Arabio will export its products to the Gulf region as well as to Yemen, Iraq, Jordan, Lebanon, Palestine, Syria, Sudan, Egypt, Libya, Algeria, Tunisia, Morocco & Mauritania. The company has also the rights to export to some African countries, including Eritrea, Ethiopia, Somalia, Djibouti and other Islamic countries.
Dr. Bahatheq added that Arabio was founded due to unwavering support from the KSA government as well as some prestigious Saudi companies, in addition to other Arab and Muslim companies, including Reaya Holding, Mohammad Saeed Tamer for Commercial Investment, The Arab company for Pharmaceutical Industries and Medical Appliances (ACDIMA), The Islamic Corporation for the Development of the Private Sector and The Holding Company for Biological Products and Vaccines in Egypt.
Arabio's manufacturing plant is located in the industrial city in Makkah and occupying an area of 10,000 square meters. The company assumed its manufacturing operations last August 2011 and produced nearly 500,000 doses of meningitis conjugated and penta-valent vaccines ( DTPw-HB+Hib) since its inception in the form of "vials".
The plant is equipped with the state of the art machines and modern equipments, and has been established according to the latest international standards meeting the requirements of US-FDA, The Saudi Food and Drug Authority (SFDA), the European agency for the registration of pharmaceuticals EMEA and The World Health Organization (WHO).
Arabio have signed a technology transfer agreement with Novartis Vaccines & Diagnostics at which Arabio will manufacture all Novartis Vaccines at Arabio facility in Makkah. Novartis is one of the world's research based pharmaceutical companies & considered as one of the major vaccines suppliers worldwide.
The Plant has started the manufacturing of the newly developed conjugated vaccine for meningitis (Menveo), in addition to seasonal influenza vaccine (Agrippal) and Penta valent vaccine (Quinvaxem) against whooping cough, diphtheria, tetanus and haemophilus influenza and hepatitis B and other necessary vaccines.
Dr. Barham added: "Arabio is looking forward to have its products the UAE market via Alphamed. We regard Arabio a new pillar of the healthcare industry in the Arab world and in the area of preventive medicine."
© Press Release 2012
